You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on prostate cancer.
Called Proclarix, the test combines the levels of two proteins with free and total PSA and patient age to assess risk of clinically significant prostate cancer.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The system, called Galen Prostate, uses a proprietary algorithm to help pathologists detect and grade prostate cancer in biopsies.
Opko recorded $177.9 million in service revenues, $32 million in product revenues, and $14.4 million from licensing and the transfer of intellectual property revenues.
Billable test volume for the company's ConfirmMDx prostate cancer test fell 5 percent year over year, but global volume for its SelectMDx test rose 61 percent.
The company's approach involves using both fluorescence in situ hybridization and next-generation sequencing to provide clinicians with information.
The firm said that in fiscal Q2, its China businesses continued to achieve greater than 20 percent growth, but its European business growth was soft year over year.
Formerly called OncoCell MDx, the Royal Oak, Michigan-based firm aims to complete a validation study for the prostate cancer risk assay within the next two months.
The group aims to validate the tool, called OncoWatch, in a study involving nine countries this year.
Most diagnostics companies saw increases in share prices compared to last year, resulting in a significant jump in the 360Dx Index.